Betting on Beads

Four year old Luminex appears to be in the right place at the right time, but it faces increasing competition in a confusing field. The company has, in only a few short years, launched two generations of products, completed a successful IPO, and captured the attention of life scientists, who are scrambling for inexpensive, fast tools that can do genetic and proteomic analysis. Luminex has a simple-to-use multiplexing platform, which is flexible and inexpensive enough to be easily adapted to fields as diverse as genomics and clinical diagnostics.

by Wendy Diller

G. Walter Loewenbaum, an investment banker in Austin, TX, gets a thrill out of seeding start-up companies—and so he was...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo